trk-in-9

Trk-IN-9 (Compound 12) is a potent inhibitor of TRK that inhibits the proliferation of Km-12 cell lines and induces apoptosis in a concentration-dependent manner. It also inhibits TRK phosphorylation and blocks downstream pathways, showing potential for NTRK fusion cancer research.

TRK-IN-29 (Compound B31) is a second-generation TRK inhibitor with IC50 values of 9 nM for TRKAG595R, 0.6 nM for TRKAF589L, 18 nM for TRKAG667C, 5 nM for TRKA, and 6 nM for TRKC. It effectively inhibits the phosphorylation of TRKA and demonstrates significant antiproliferative activity against NTRK fusion-positive cells. TRK-IN-29 also exhibits excellent plasma stability and moderate pharmacokinetic properties.

TRK-IN-23 is a kinase inhibitor and a potent, oral second-generation TRK inhibitor (TRKA IC50 = 0.5 nM). It overcomes clinical resistance mutations like G595R in cancer research.